V' This randomized double-blind placebo-controlled study was undertaken in a series of 179 patients to determine whether phenytoin administered soon after head injury lessens the incidence of late posttraumatic epilepsy. When delayed hypersensitivity to phenytoin developed, the patient was switched to phenobarbital. The patients were followed for 18 months to detect the occurrence of seizures and to serially measure plasma phenytoin concentrations. There was no significant difference in the percentage of patients having late seizures in the treated and placebo groups (p = 0.75). The time between injury and seizures did not significantly differ between the two groups. The results provide no support for the continued use of phenytoin in the low therapeutic range for prophylaxis against late posttraumatic seizures.
D
O prophylactically administered anticonvulsant drugs decrease the incidence of posttraumatic seizures in head-injured patients? Whether anticonvulsant therapy should be used prophylactically is an important public health issue, since an estimated 422,000 persons each year are hospitalized in the United States for head injury. At least 10% of hospitalized head-trauma patients suffer severe injuries. The National Head and Spinal Cord Injury Survey 8 established that 20% of head-trauma patients had a first hospital stay of 5 to 9 days, and an additional 10% (over 40,000) were hospitalized for 20 or more days. A survey of board-certified neurosurgeons in 1973 revealed that 60% used prophylactic anticonvulsant drugs in patients with severe head injury. 15 Several recent uncontrolled studies have supported this practice by indicating that posttraumatic seizures can be prevented by prophylactically administering anticonvulsant drugs.13, 21, 22 We report the results of a randomized double-blind placebo-controlled study showing that the incidence of late posttraumatic epilepsy is not decreased by prophylactically administering phenytoin.
Clinical Material and Methods

Patient Population
This study was undertaken to determine whether phenytoin administered soon after head injury lessens the incidence of late posttraumatic epilepsy. The patients comprising this study were admitted to the University of Kentucky Neurosurgical Service between December, 1976, and November, 1979 . Only those patients estimated to have 15% or greater prob-Failure of phenytoin in late posttraumatic seizures ability of developing late posttraumatic epilepsy were included in the study. 2-4,7A2A6 At the outset, the study included 178 males and 36 females. Mean age was 25.2 years; 4.7% of the patients were less than 5 years of age, 17.3% were between 5 and 16 years of age, and 78.0% were over 16 years of age. The patient population selected for this study, and the method of randomization and phenytoin administration* during the 1st week after head injury are identical to those described in our immediately preceding study, z3 The major difference in the methods of this study is the much longer duration of phenytoin administration and time of observation for seizure occurrence. We attempted to maintain all patients on phenytoin for the entire 18 months. When delayed hypersensitivity to phenytoin developed, the patient was switched to phenobarbital. Diazepam was occasionally used to control status epilepticus occurring during the 1st week after injury.
We attempted to follow all of the patients for 18 months to detect the occurrence of seizures and to serially measure plasma phenytoin concentrations. Every effort was made to interview and examine each patient in our outpatient department; however, in some cases, written or telephone reports were necessary to obtain a full 18 months of follow-up review. To provide compatibility with other studies, "late posttraumatic epilepsy" was defined as one or more seizures occurring at least 1 week after head injury without any other obvious cause. Only seizures occurring at or after 1 week postinjury were used to assess the effectiveness of posttraumatic epilepsy prophylaxis. When a single seizure occurred, patients on phenytoin were considered seizure prophylaxis failures. Patients having a single seizure while receiving placebo were placed on phenytoin. Once a seizure occurred in either group the patients were removed from the study for the purpose of this report.
Clinical management, including surgery, intraventricular pressure monitoring, administration of dexamethasone, hypertonic solutions, and antibiotic drugs, was dictated by the nature of the patient's brain injury, based on current standards of optimal neurosurgical treatment. All patients received medications in addition to phenytoin; however, none received other anticonvulsant drugs unless they developed hypersensitivity to phenytoin or experienced uncontrolled seizures.
Our goal was to administer sufficient phenytoin to immediately achieve and then maintain the plasma phenytoin concentration between 10 and 20 /zg/ml throughout the 18 months of the study. The success of this effort was judged by frequent phenytoin assays during the 1st week following injury and every 2 to 3 * All phenytoin (Dilantin) injectable, suspension, and capsules, both active drug and placebo, were generously supplied by Warner-Lambert (Parke-Davis) Research Laboratories, Ann Arbor, Michigan. days during the remaining period of hospitalization. Outpatient assays were planned for I, 3, 6, 9, 12, 15, and 18 months after the injury. More frequent assays were carried out when the plasma phenytoin concentration was not within the desired range or when the patient's clinical condition required more frequent outpatient visits.
Statistical Methods
Comparison of the phenytoin group and the group of patients randomized to phenytoin who were switched to phenobarbital, as well as comparison of the active drug and placebo groups, depended on the type of data being studied. Categorical data were analyzed using a chi-square test or, when expected cell frequencies were low, Fisher's exact test. Group comparisons using continuous data were measured by the independent samples t-test with the exception of days to late seizure and days to death, which were analyzed using Gehan's test? Gehan's test is an extension of the Mann-Whitney test for comparing two independent groups. Time to event or time of followup were compared for all pairs of observations; one member of the pair coming from the active drug group, the paired member from the placebo group. A score of + 1 or -1 is given when censoring makes a direct comparison impossible. (The eleven patients lost to follow-up review were included when the Gehan tests were run. Ignoring these patients changed the results little.) The Statistical Analysis System was used for all analyses including the Gehan test which required special progranuning.t
Results
Of the 214 patients included at the outset, 179 were followed for at least 18 months (Table 1) . Eleven patients were lost to follow-up review. Twenty additional patients were randomized into the study but are not included in the data analysis since they did not survive beyond the 1st week after the head injury and, by definition, could not have had a late posttraumatic seizure. Four other patients who were randomized to the placebo group were eliminated: three of these were given phenytoin following an early seizure, and one was given phenobarbital to control elevated intracranial pressure. Of the patients who survived 1 week and who were followed for 18 months, 85 received phenytoin, 20 received phenytoin initially but were later switched to phenobarbital, and 74 received placebo ( Table 1) . The difference in size of the drug and placebo groups is a chance occurrence. No significant differences exist between the characteristics of the drug group (phenytoin and phenytoin plus phenobarbital) and the placebo group (Table 2) or between the * These patients were randomized to placebo but switched to phenytoin after an early seizure. t This patient received phenobarbital in the 1st week after injury to control elevated intracranial pressure.
phenytoin and phenytoin plus phenobarbital subgroups (Table 3 ).
There was no significant difference in the percentage of patients having late seizures in the phenytoin group and the phenytoin patients who were switched to phenobarbital: late seizures occurred in 11 of 85 (12.9%) patients in the phenytoin group and in two of 20 (10.0%) in the phenytoin group who were switched to phenobarbital (p = 0.48, Fisher's exact test; Table  4 ). Eight of 74 (10.8%) control patients had late sei- zures. This percentage does not vary significantly from the overall drug group figure of 13 among 105 patients or 12.4% (p = 0.75, Table 4 ). Seven of the drug patients had grand mal seizures and six had focal seizures. Five placebo patients had a grand mal seizure and three had a focal seizure. Table 5 lists the compliance figures. The sample sizes are small after 6 months. At 6 months, over onehalf of the patients with known blood levels of phenytoin were compliant, but this represents only about one-fourth of the initial patients given phenytoin. Table 6 relates sustained phenytoin blood concentrations to subsequent seizure occurrence. The patients included in this table maintained phenytoin plasma concentrations at every clinic visit for the level and interval listed. The percent of seizures refers only to seizures subsequent to the period of sustained drug administration. The percentage of patients having seizures is very similar for the group that maintained phenytoin blood levels at least at 10 #g/ml for 3 months (8.3%) and the control group (10.8%). A larger percentage of patients maintaining high phenytoin blood concentrations for 3 months had subsequent seizures than did the patients who maintained high phenytoin concentrations for 1 month. The number of patients in which this factor could be analyzed is small.
We determined the phenytoin plasma concentrations on the next clinic visit after the occurrence of the first seizure. None of the 11 phenytoin patients who had just experienced a seizure had a plasma concentration above 12 ~tg/ml. Only two patients had a phenytoin plasma concentration above 10/zg/ml. Four patients who had a seizure had plasma concentrations between 5 and 10/~g/ml, one had a plasma phenytoin concentration between 0 and 5/tg/ml, and four had no detectable phenytoin.
The median time to death was 16 days for the drug group (range 8 to 54 days) and 14.5 days for the placebo group (range 9 to 90 days). The median time to late seizure was 30 days for the drug group (range 8 to 450 days) and 110 days for the placebo group (range 10 to 450 days). Gehan tests of time to death and time to late seizure were run. According to the Gehan test, the times to death did not differ between the groups (standardized Gehan statistic = -1.04, p --0.30). (This test considered all 190 patients who survived at least 1 week. The variable times of followup review or times to death were compared.) Nor did 
Discussion
This randomized double-blind placebo-controlled study shows that phenytoin administered soon after head injury and continued for 18 months does not decrease the incidence of posttraumatic seizures as compared to a similar group of patients receiving placebo. These results differ with the findings of several other studies. The most recent report on this subject is Wohns and Wyler's retrospective analysis of 62 patients with severe head injury. 21 They concluded that "prophylactically administered phenytoin is effective in reducing posttraumatic epilepsy." These authors point out the major deficiencies in the clinical design of their study, particularly the retrospective nonrandomized nature of the study, which severely limits the validity of their findings. Our results also differ with Popek's report 13 that only 1.1% of the patients receiving both phenytoin and phenobarbital had late seizures compared with 25% of the patients in the control group. This study was not randomized, placebo-controlled, or double-blinded.
In a previous report, Young, et al., 22 also suggested that phenytoin reduces the incidence of late posttrau-matic seizures. This study was not controlled by randomization. Their conclusions were based on comparisons with other large clinical series published up to 1979. The seizure rate of 6% during the 1st year after head injury in that series, in which all patients received phenytoin, is almost identical to the 7.1% rate reported in 1980 by Annegers, et al.fl in a series of severely head-injured patients who were considered by these authors as untreated.
Analysis of the prophylactic anticonvulsant drug regimen used during the Vietnam war showed that the "incidence of posttraumatic epilepsy in those with a continuous medical regimen was somewhat greater than the incidence in those with an interrupted or no medical regimen. ''3 Anticonvulsant drugs were initiated within 24 hours of injury in 84% of these men, intramuscularly if necessary. Phenytoin alone was given to 75%; an additional 20% received both phenytoin and phenobarbital. Phenytoin doses were 300 to 400 mg/day and phenobarbital doses were 96 nag/ day. Blood levels of the drugs were not assayed. The findings of this study with regard to the effectiveness of posttraumatic seizure prophylaxis are very similar to our results.
The risk of posttraumatic seizure in our current study was similar to the risk reported by Annegers, et al., 1 in their retrospective study of a civilian population. Late seizures occurred in 7.1% of their patients within the 1st year following severe head injury. During the 1st year of our study, 10.9% of patients had had at least one seizure. Detailed data about anticonvulsant prophylaxis in their study are not provided. The authors state that "essentially, the cases form an untreated cohort, for in only 17 of them was such treatment continued for 6 months or more." The number of patients given anticonvulsant drugs for less than 6 months was not reported. Since a prophylactic effect could possibly be achieved by treatment lasting a few months, a considerably larger number of patients than 17 may have received adequate drug doses for prophylaxis.
Our findings also contrast with a large body of experimental evidence that anticonvulsant prophylaxis tends to prevent epilepsy induced by a variety of epileptogenic insults, n,14,17-2~ The design of our clinical study corresponds with Rapport and Ojemann's study of cobalt-induced epilepsy in cats. TM Administering phenytoin prophylactically for 28 days prevented the seizures that usually develop in this animal model. Those authors suggested that prophylactically administered phenytoin prevented the maturation of the epileptogenic focus and that phenytoin was an effective prophylactic drug. Our study suggests that phenytoin does not prevent or alter the rate of development of the epileptogenic focus in humans, since the incidence of seizures and the time to first seizure were not significantly different in the treated and untreated groups. Prophylaxis implies that the anticonvulsant drug could be given for a short interval, perhaps even at a dose lower than necessary for a therapeutic or suppressive effect. Our study indicates that maintaining blood levels of at least 10/tg/ml for 3 months is no more effective than placebo, but the numbers of patients are too small to reach valid statistical comparisons.
Even though there is no significant difference in the death rate between the treated and untreated groups, the death rate is about 6% lower in the treated group (18.9% for the placebo group and 12.4% for the drug group, p ---0.23). The failure of a prophylactic effect cannot, however, be accounted for by the longer survival (and thus longer time at risk for seizure occurrence) of the treated group. Although time to death is slightly longer in the drug group, time to seizure is shorter. This finding does not support the contention that the lack of a significant difference in seizure incidence between the two groups occurs because treated patients live longer and therefore have more seizures.
Our data indicate that the early initiation and continued administration of phenytoin and phenytoin followed by phenobarbital does not lessen the occurrence of posttraumatic epilepsy. Our findings suggest that phenytoin at the blood levels obtained in our study did not have a prophylactic effect by preventing the development of the epileptogenic focus. Our resuits provide no support for the continued use of phenytoin in doses sufficient to provide blood concentrations in the low therapeutic range for prophylaxis against late posttraumatic seizures.
We cannot conclude that higher phenytoin plasma concentrations and higher compliance rates than obtained in our study would not have significantly decreased the occurrence of late posttraumatic epilepsy by causing a suppressive effect upon the developed epileptogenic focus. The question of whether higher therapeutic blood levels of phenytoin would decrease the occurrence of late seizures is unresolved. If phenytoin is used for late seizure prophylaxis, our results suggest that only doses providing high therapeutic blood levels which are proven to be consistently maintained by frequent phenytoin plasma assays can be justified. Whether this regimen would be effective remains unproven. Our finding that no patient with a phenytoin plasma concentration of 12 #g/ml or higher had a seizure raises the question of whether high therapeutic doses might lessen the occurrence of posttraumatic epilepsy, and should be studied further. The difficulties in obtaining a high rate of compliance with drug plasma levels in the high therapeutic range for a prolonged time in head-injured patients would make this a difficult goal to achieve. Several reports document the difficulties in maintaining compliance for a long time in epileptic patients. 6,9,1~ Notwithstanding these obstacles, posttraumatic epilepsy is a major public health problem, deserving a large cooperative trial to determine if phenytoin at higher blood levels than obtained in our study, or other currently avail-Failure of phenytoin in late posttraumatic seizures able or newly developed drugs, can prevent the occurrence of posttraumatic epilepsy.
